In 24 adults with type 2 diabetes randomised to dapagliflozin (n=17) or placebo (n=7) for 6 months, LDL-ApoB100 fractional catabolism was unchanged (0.88 vs 0.79 pool/day, p=0.16); VLDL1 catabolism shifted from direct to indirect pathways.
RCTn = 24
Vergès et al. Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study